The new plant will feature zero liquid discharge (ZLD) technology and an advanced effluent treatment plant, designed to cut energy use by 70 per cent and recover 90-95 per cent of wastewater, aligning with global ESG and compliance standards.
Visakhapatnam: Blue Jet Healthcare Ltd will break ground on Saturday on a Rs 2,300-crore greenfield pharmaceutical manufacturing facility at Rambilli Industrial Park in Anakapalli district, Andhra Pradesh, marking a major expansion of India’s specialty pharma and CDMO capabilities.
Spread across 102 acres, the facility will produce contrast media intermediates, high-intensity sweeteners, and multipurpose chemistry products. Developed in phases, it is expected to be operational by FY2028-29, official sources said.
The project is projected to generate 1,750 direct and 250 indirect jobs, strengthening the Visakhapatnam industrial region.
Founded in 1968 as Jet Chemicals Pvt Ltd, Blue Jet Healthcare has grown into an integrated Contract Development and Manufacturing Organisation (CDMO), supplying advanced pharmaceutical intermediates and APIs to markets in India, Europe, and the US.
The company is a leading player in contrast media intermediates and an early pioneer of saccharin production in India.
Over decades, it has built deep expertise in process chemistry, manufacturing scale-up and global regulatory-compliant production, positioning itself as a strategic supplier to multinational pharmaceutical companies.
The new plant will feature zero liquid discharge (ZLD) technology and an advanced effluent treatment plant, designed to cut energy use by 70 per cent and recover 90-95 per cent of wastewater, aligning with global ESG and compliance standards.
